CTSO Cytosorbents Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTSO

Price (delayed)

$0.48

Market cap

$30.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.19

Enterprise value

$52.52M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 33

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the ...

Highlights
The gross profit rose by 9% year-on-year
Cytosorbents's revenue has increased by 5% YoY
CTSO's EPS is down by 46% from the previous quarter but it is up by 34% YoY
CTSO's net income is down by 45% since the previous quarter but it is up by 26% year-on-year
The equity has dropped by 85% year-on-year and by 63% since the previous quarter
The quick ratio has shrunk by 61% YoY and by 47% QoQ
Sector: Healthcare
Industry: Medical Devices
Website: http://www.cytosorbents.com
Peers: BSX NEPH

Key stats

What are the main financial stats of CTSO

CTSO stock price

How has the Cytosorbents stock price performed over time
Intraday
-1.84%
1 week
-3.19%
1 month
-22.59%
1 year
-52%
YTD
-24.91%
QTD
-15.24%

Financial performance

How have Cytosorbents's revenue and profit performed over time
Revenue
$37.2M
Gross profit
$26.41M
Operating income
-$13.91M
Net income
-$11.85M
Gross margin
71%
Net margin
-31.9%
CTSO's net income is down by 45% since the previous quarter but it is up by 26% year-on-year
The net margin has declined by 44% since the previous quarter but it has increased by 30% year-on-year
Cytosorbents's operating margin has increased by 16% YoY and by 6% QoQ
CTSO's operating income is up by 11% year-on-year and by 6% since the previous quarter

Price vs fundamentals

How does CTSO's price correlate with its fundamentals

Growth

What is Cytosorbents's growth rate over time

Valuation

What is Cytosorbents stock price valuation
P/E
N/A
P/B
13.72
P/S
0.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.41
CTSO's EPS is down by 46% from the previous quarter but it is up by 34% YoY
CTSO's P/B is 197% higher than its 5-year quarterly average of 4.7 and 54% higher than its last 4 quarters average of 9.1
The equity has dropped by 85% year-on-year and by 63% since the previous quarter
The stock's price to sales (P/S) is 71% less than its 5-year quarterly average of 2.8 and 45% less than its last 4 quarters average of 1.5
Cytosorbents's revenue has increased by 5% YoY

Efficiency

How efficient is Cytosorbents business performance
The ROE has plunged by 107% from the previous quarter and by 42% YoY
The ROIC has plunged by 65% from the previous quarter but it has grown by 37% YoY
CTSO's ROS has plunged by 56% from the previous quarter but it is up by 44% YoY
The ROA has shrunk by 53% QoQ but it has increased by 18% YoY

Dividends

What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTSO.

Financial health

How did Cytosorbents financials performed over time
The company's total assets is 6% higher than its total liabilities
The quick ratio has shrunk by 61% YoY and by 47% QoQ
CTSO's current ratio has dropped by 58% year-on-year and by 49% since the previous quarter
The debt to equity has soared by 170% since the previous quarter
The equity has dropped by 85% year-on-year and by 63% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.